China Universal Asset Management Co. Ltd. Acquires 2,157 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

China Universal Asset Management Co. Ltd. raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 10.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,480 shares of the biopharmaceutical company’s stock after purchasing an additional 2,157 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Intra-Cellular Therapies were worth $1,878,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. True Wealth Design LLC purchased a new position in shares of Intra-Cellular Therapies during the third quarter valued at approximately $32,000. GAMMA Investing LLC increased its position in Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares during the period. Capital Performance Advisors LLP purchased a new position in Intra-Cellular Therapies during the 3rd quarter valued at $74,000. Wilmington Savings Fund Society FSB bought a new position in Intra-Cellular Therapies in the 3rd quarter worth $97,000. Finally, Quarry LP lifted its position in shares of Intra-Cellular Therapies by 260.0% in the 3rd quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,300 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Up 0.1 %

Shares of NASDAQ ITCI opened at $127.08 on Friday. The firm’s 50 day moving average price is $97.45 and its 200-day moving average price is $84.45. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The business had revenue of $175.40 million during the quarter, compared to the consensus estimate of $172.30 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business’s revenue was up 39.0% compared to the same quarter last year. During the same period last year, the company posted ($0.25) earnings per share. As a group, research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Insider Transactions at Intra-Cellular Therapies

In other news, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $89.12, for a total value of $2,038,085.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Sharon Mates sold 51,000 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

ITCI has been the topic of several research analyst reports. Piper Sandler reiterated a “neutral” rating and set a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their target price for the stock from $119.00 to $132.00 in a research report on Friday. Morgan Stanley lifted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Needham & Company LLC restated a “hold” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.62.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.